Anixa Biosciences (NASDAQ:ANIX) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Anixa Biosciences (NASDAQ:ANIX) released its quarterly earnings data on Wednesday. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.02, Fidelity Earnings reports.

Shares of NASDAQ ANIX opened at $4.33 on Friday. Anixa Biosciences has a twelve month low of $1.70 and a twelve month high of $8.09. The company has a market cap of $136.10 million, a P/E ratio of -3.83 and a beta of 1.41. The firm has a 50 day moving average price of $4.32.

In related news, Director Arnold M. Baskies acquired 10,000 shares of the stock in a transaction that occurred on Thursday, March 25th. The stock was purchased at an average cost of $4.80 per share, for a total transaction of $48,000.00. Following the purchase, the director now directly owns 15,600 shares in the company, valued at $74,880. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders bought a total of 30,000 shares of company stock valued at $137,150 over the last quarter. Company insiders own 19.80% of the company’s stock.

ANIX has been the topic of several recent research reports. Zacks Investment Research lowered Anixa Biosciences from a “buy” rating to a “hold” rating in a research report on Tuesday, April 27th. HC Wainwright reissued a “buy” rating and set a $11.00 price target on shares of Anixa Biosciences in a research report on Friday, May 21st. Finally, Aegis reaffirmed a “buy” rating on shares of Anixa Biosciences in a research report on Monday, February 15th.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain viral protein functions of the virus.

See Also: Special Purpose Acquisition Company (SPAC) – What You Need to Know

Earnings History for Anixa Biosciences (NASDAQ:ANIX)

Receive News & Ratings for Anixa Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anixa Biosciences and related companies with's FREE daily email newsletter.